How’s business at Sarepta?
The past few months of conversation around Sarepta Therapeutics have, understandably, focused on its surprising FDA rejection and the question of whether its gene therapy will ever become a product. It’s easy to forget that Sarepta already has an approved drug, and that drug might be reaching its revenue peak.
On Thursday, we’ll find out just how well Exondys 51, approved to treat Duchenne muscular dystrophy, is doing on the market. The treatment got off to an impressive launch but has since approached what looks like a commercial zenith.
That shouldn’t be surprising: DMD affects about one in 5,000 boys, and Sarepta’s drug is approved only for the roughly 13% of them with a certain genetic mutation. Its revenue potential was always limited.
But the bull case for Sarepta was that the company would use the short-term Exondys 51 windfall to build a pipeline of therapies that would make for a bright future. Now that the picture has grown cloudy, analysts might have a different take on Sarepta’s revenue numbers.
On Thursday, we’ll find out just how well Exondys 51, approved to treat Duchenne muscular dystrophy, is doing on the market. The treatment got off to an impressive launch but has since approached what looks like a commercial zenith.
That shouldn’t be surprising: DMD affects about one in 5,000 boys, and Sarepta’s drug is approved only for the roughly 13% of them with a certain genetic mutation. Its revenue potential was always limited.
But the bull case for Sarepta was that the company would use the short-term Exondys 51 windfall to build a pipeline of therapies that would make for a bright future. Now that the picture has grown cloudy, analysts might have a different take on Sarepta’s revenue numbers.
No hay comentarios:
Publicar un comentario